GlassScriptPhysician profile
Larry S Tamburro
NPI 1174504930
$10,235.79
in general payments reported to CMS, 2019-2025
69 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,530 · 2020: $1,303 · 2021: $2,102 · 2022: $1,429 · 2023: $1,349 · 2024: $1,426 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,870.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,159.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,113.98 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $911.23 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $775.18 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $645.38 | 2019-2025 | Jardiance |
| Pfizer INC. | $513.86 | 2019-2025 | |
| Amgen INC. | $352.93 | 2019-2024 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $344.47 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $328.52 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $294.65 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Astellas Pharma US INC | $244.96 | 2019-2025 | Veozah |
| Abbott Laboratories | $235.93 | 2019-2024 | Proclaim, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $198.18 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $172.14 | 2022 | |
| Eisai INC. | $156.84 | 2020-2022 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Tamburro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.